Biogen announced an additional $2 billion investment over the next three years to expand its extensive manufacturing operations within North Carolina’s Research Triangle Park (RTP), reinforcing its commitment to domestic production. The expansion will enhance antisense oligonucleotide capabilities, establish fill-finish lines for clinical and commercial supply, and introduce advanced automation and artificial intelligence technologies across multiple modalities. This follows more than $10 billion previously invested at RTP, home to several Biogen factories, enabling support of late-stage pipeline programs and improving supply resilience. The move also underscores Biogen’s focus on retaining and growing skilled life sciences talent in the region.